Dr. Alexander Dobranowski reports

HEALWELL AI'S PENTAVERE ACHIEVES VALIDATION OF GENERATIVE AI FOR PREVENTATIVE CARE THROUGH LANDMARK PUBLICATION

Healwell AI Inc.'s subsidiary Pentavere Research Group has achieved a significant milestone with the publication of a paper validating the use of generative artificial intelligence to identify rare lung cancer patients. The paper, titled "Real-world Outcomes of Patients with Advanced Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in Canada Using Data Extracted by Large Language Model-Based Artificial Intelligence," marks an important moment in the application of AI in precision oncology. This landmark publication is the industry's first peer-reviewed paper utilizing AI and large language models to identify rare lung cancer patients using real-world electronic health record data, supporting precision oncology efforts, and it showcases Healwell's leadership position in developing AI technology applications in health care.

Aaron Leibtag, chief executive officer of Pentavere, commented: "Pentavere is pushing the boundaries of innovation in health care and leveraging AI to address the most pressing challenges facing patients and health care providers. We have harnessed this capability into very productive work with world-leading pharma and cancer centres to help optimize patient care in lung cancer. We've developed best-in-class AI that is core to our mission of preventative care. This paper highlights our ability to use generative AI in the real world to unlock key clinical and commercial value."

Dr. Alexander Dobranowski, CEO of Healwell, added: "We are immensely proud of the Pentavere team, and the innovative research showcased in this publication. This milestone validates the power of fine-tuned generative AI to drive meaningful insights and transform patient care. This pioneering research will set a new standard for the utilization of advanced technology in health care. We remain committed to leveraging AI to improve outcomes for patients worldwide."

As evidenced in the paper, through the innovative use of AI and large language models, Pentavere has successfully extracted one of the largest population cohorts of advanced rare EGFRexon20 lung cancer patients for use as real-world evidence. This data set has provided valuable insights into unmet patient needs, to support more effective cancer treatments.

Industry leaders such as Johnson & Johnson Innovative Medicine co-authored this paper to support scientific research and improve patient care. Globally recognized clinical oncologists from Princess Margaret Cancer Centre are also authors on this paper and are using these data to enhance the quality of cancer care for their patients.

The ability to analyze the large amounts of unstructured clinical documentation within the electronic health record at scale using generative AI has opened new avenues for improving patient outcomes and advancing precision medicine initiatives.

About Healwell AI Inc.

Healwell is a health care technology company focused on AI and data science for preventive care. Its mission is to improve health care and save lives through early identification and detection of disease. Using its own proprietary technology, the company is developing and commercializing advanced clinical decision support systems that can help health care providers detect rare and chronic diseases, improve efficiency of their practice, and ultimately help improve patient health outcomes. Healwell is executing a strategy centred around developing and acquiring technology and clinical sciences capabilities that complement the company's road map. Healwell is publicly traded on the Toronto Stock Exchange under the symbol AIDX and on the OTC Exchange under the symbol HWAIF.

About Pentavere Research Group

Pentavere Research Group is a globally recognized and award-winning AI digital health company that has built a best-in-class AI engine to identify patients that are eligible for approved medications or interventions, to improve outcomes for patients, and help drive therapy growth and penetration. Pentavere's AI system, Darwen, identifies patients that are eligible for but not receiving approved medications or interventions, improving outcomes for patients and helping drive appropriate therapy growth and penetration.

We seek Safe Harbor.